LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of $30.00. The company’s shares clo ...

Analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Zymeworks in a research note issued to investors on ...

Equities research analysts at Lifesci Capital issued their FY2024 earnings per share (EPS) estimates for shares of Immunome in a note issued to investors on Tuesday, March 11th. Lifesci Capital ...

In a report released today, Charles Zhu from LifeSci Capital initiated coverage with a Buy rating on Protara Therapeutics (TARA – Research ...

In a report released today, Charles Zhu from LifeSci Capital initiated coverage with a Buy rating on Molecular Partners (MOLN – Research ...

Proscia sells digital pathology software and artificial intelligence tools to pharmaceutical companies and diagnostic ...

An Oxford-based company which pioneers AI-powered imaging tools for stroke and lung fibrosis has completed a £14m Series C investment round.

Brainomix, a company pioneering AI-powered imaging tools in stroke and lung fibrosis, today announced the completion of a ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea ...